BTK and B-cell chronic lymphocytic leukemia: Chemotherapy has been the milestone for CLL treatment for decades, while therapeutic options have significantly expanded in the last decade, with the introduction of continuous therapy with BTK inhibitors and fixed-duration regimens with anti-CD20 monoclonal antibodies (rituximab, obinutuzumab) plus venetoclax, or the recent combination with ibrutinib-venetoclax.